NCT03492554

Brief Summary

The purpose of the study is to confirm the software's ability to create a Lead-1 electrocardiogram (ECG) that is clinically equivalent to a reference device. Also, to confirm a rhythm classification algorithm and its ability to detect and classify heart rhythms into two categories (Sinus Rhythm or Atrial Fibrillation) using a single Lead ECG.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
602

participants targeted

Target at P75+ for not_applicable atrial-fibrillation

Timeline
Completed

Started Mar 2018

Shorter than P25 for not_applicable atrial-fibrillation

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 27, 2018

Completed
13 days until next milestone

Study Start

First participant enrolled

March 12, 2018

Completed
29 days until next milestone

First Posted

Study publicly available on registry

April 10, 2018

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 14, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 14, 2018

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

July 24, 2019

Completed
Last Updated

December 3, 2020

Status Verified

November 1, 2020

Enrollment Period

2 months

First QC Date

February 27, 2018

Results QC Date

May 13, 2019

Last Update Submit

November 19, 2020

Conditions

Outcome Measures

Primary Outcomes (2)

  • Number of Participants With Software's Rhythm Classification of SR in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG

    Specificity of rhythm classification

    1 Day

  • Number of Participants With Software's Rhythm Classification of AF in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG

    Sensitivity of rhythm classification

    1 Day

Secondary Outcomes (3)

  • Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference

    1 Day

  • Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference

    1 Day

  • Ease of Use

    1 Day

Study Arms (2)

Atrial fibrillation (AF)

OTHER

Patient with a known history of AF who are in AF at the time of study screening.

Other: 1-Lead ECGDevice: 12-Lead ECG

Normal Sinus Rhythm (SR)

OTHER

Patient with no known diagnosis of AF or other arrhythmia

Other: 1-Lead ECGDevice: 12-Lead ECG

Interventions

All participants will record three single-lead ECGs

Atrial fibrillation (AF)Normal Sinus Rhythm (SR)

All participants will simultaneously record three 12-lead ECGs

Atrial fibrillation (AF)Normal Sinus Rhythm (SR)

Eligibility Criteria

Age22 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Individuals who are 22 years of age and older
  • Able to read, understand, and provide written informed consent
  • Willing and able to participate in the study procedures as described in the consent
  • Have a wrist circumference that fits within the band
  • Able to communicate effectively with and follow instructions from the study staff
  • For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening

You may not qualify if:

  • Physical disability that precludes safe and adequate testing
  • Mental impairment resulting in limited ability to cooperate
  • Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD)
  • Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable
  • Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening
  • Stroke or transient ischemic attack within 90 days of screening
  • Subjects taking rhythm control drugs
  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites
  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices
  • A history of abnormal life-threatening rhythms as determined by the investigator
  • Significant tremor that prevents subject from being able to hold still
  • Pregnant women: Women who are pregnant at the time of study participation
  • For subjects enrolled into the sinus rhythm population, they must not have any diagnosis of AF

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

QPS

Miami, Florida, 33143, United States

Location

BioClinicia- Orlando

Orlando, Florida, 32806, United States

Location

BioClinica- The Villages

The Villages, Florida, 32162, United States

Location

IQVIA

Overland Park, Kansas, 66211, United States

Location

Health East

Saint Paul, Minnesota, 55102, United States

Location

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

Electrocardiography

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Heart Function TestsDiagnostic Techniques, CardiovascularDiagnostic Techniques and ProceduresDiagnosisElectrodiagnosis

Results Point of Contact

Title
Health Technology Clinical Operations
Organization
Apple

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2018

First Posted

April 10, 2018

Study Start

March 12, 2018

Primary Completion

May 14, 2018

Study Completion

May 14, 2018

Last Updated

December 3, 2020

Results First Posted

July 24, 2019

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will not share

Locations